Kim Kjoller, MD: Tralokinumab for Atopic Dermatitis


Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.

Earlier this month, the US Food and Drug Administration (FDA) accepted LEO Pharma’s Biologics License Application for tralokinumab for the treatment of adults with moderate to severe atopic dermatitis. The acceptance was the beginning of the agency’s formal review procedure of the biologic.

Atopic dermatitis is a very heterogenous disease and experts do not expect 1 solution to work on every patient, Kim Kjøller, MD, executive vice president of global research & development at LEO Pharma, said in a recent interview with HCPLive®. The dermatology field needs more treatment options to come out, and tralokinumab is a unique choice.

“It’s unique in the sense that, provided it achieves regulatory approval, it will be the first selective IL-13 biologic that people will have to treat atopic dermatitis,” Kjøller said.

That’s interesting because when looking at the science behind it, IL-13 seems to be the most prominent of the cytokines driving atopic dermatitis, he said. The treatment could be extremely beneficial for those suffering from the condition.

As more data come out on biologic treatment, experts have seen it takes a little while to see skin clearance, but early on, patients reported significant improvement in itch and quality of life. Such information shows the treatment is starting to work.

Related Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
© 2024 MJH Life Sciences

All rights reserved.